For Healthcare Professionals

CHOLBAM® (cholic acid) capsules may help patients with bile acid synthesis disorders due to single enzyme defects and patients with liver involvement in Zellweger spectrum disorders

CHOLBAM is the FIRST and ONLY FDA-APPROVED treatment indicated for
CHOLBAM® is indicated for:

  • Treatment of bile acid synthesis disorders due to single enzyme defects
  • Adjunctive treatment of peroxisomal disorders, including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption

CHOLBAM® may help restore normal liver function
Treatment with CHOLBAM®:

  • Restores normal balance of bile acids that improve bile flow
  • Prevents accumulation of hepatotoxic atypical bile acids that may lead to liver damage
  • Helps regulate physiological feedback inhibition via the farnesoid X receptor (FXR)
FREE Atypical Bile Acid Test for Cholestasis for Qualifying Patients
Travere Therapeutics is invested in the well-being of patients with bile acid synthesis disorders and has partnered with Cincinnati Children's Hospital Medical Center to offer a free laboratory test. This urinary bile acid profile test by Fast Atom Bombardment Mass Spectrometry (FAB-MS) is only performed at Cincinnati Children's Hospital Medical Center (CCHMC). Download the Atypical Bile Acid Test overview below for more information

Bile Acid Synthesis Disorders Atypical Bile Acid Test Program Overview
FREE Atypical Bile Acid Test for Zellweger Spectrum Disorders for Qualifying Patients
Travere Therapeutics is invested in the well-being of patients with Zellweger spectrum disorders and has partnered with Cincinnati Children's Hospital Medical Center to offer a free laboratory test. This test will help identify the presence and concentration levels of dihydroxy- and trihydroxycholestanoic acid (DHCA/THCA), atypical bile acids which can be hepatotoxic and associated with liver disease. Visit ZSDlivertest.com or click on link below for more information and to order the free Atypical Bile Acid Test program materials for Zellweger Spectrum Disorders.

Free Atypical Bile Acid Test Information

CHOLBAM® (cholic acid) capsules, for oral use [prescribing information]. San Diego, CA: Travere Therapeutics, Inc.; March 2015.

Indication and Usage
CHOLBAM® is a bile acid indicated for:

  • Treatment of bile acid synthesis disorders due to single enzyme defects
  • Adjunctive treatment of peroxisomal disorders including Zellweger spectrum disorders in patients who show signs and symptoms of liver disease, steatorrhea (fatty stools), or complications from decreased fat soluble vitamins absorption (A, D, E, K)

Limitation of Use:
The safety and effectiveness of CHOLBAM® on extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorder including Zellweger spectrum disorders have not been established.

Important Safety Information
Warnings and Precautions—Exacerbation of Liver Impairment

  • Monitor liver function and discontinue CHOLBAM® (cholic acid) in patients who develop worsening of liver function while on treatment.
  • Monitor AST, ALT, GGT, alkaline phosphatase, bilirubin, and international normalized ratio (INR) every month for the first 3 months, every 3 months for the next 9 months, every 6 months during the next 3 years and annually thereafter. Administer the lowest dose that effectively maintains liver function.
  • Discontinue CHOLBAM® if liver function does not improve within 3 months of starting treatment, if complete biliary obstruction develops, or if there are persistent clinical or laboratory indicators of worsening liver function or cholestasis; continue to monitor liver function and consider restarting at a lower dose when parameters return to baseline.

Adverse Reactions
In the CHOLBAM® clinical trials, diarrhea was the most common adverse reaction in approximately 2% of the patient population. All other adverse reactions are less than or equal to 1% of the patient population.

Drug Interaction

  • Bile Salt Efflux Pump (BSEP) Inhibitors (eg, cyclosporine): Avoid concomitant use; if concomitant use is necessary, monitor serum transaminases and bilirubin.
  • Bile Acid Resins and Aluminum-Based Antacids: Take CHOLBAM® at least 1 hour before or 4 to 6 hours (or at as great an interval as possible) after a bile acid binding resin or aluminum-based antacids.

Pregnancy
No studies in pregnant women or animal reproduction studies have been conducted with CHOLBAM®. Women who become pregnant during CHOLBAM® treatment are encouraged to call 1-844-202-6262.

Lactation
Endogenous cholic acid is present in human milk. Clinical lactation studies have not been conducted to assess the presence of CHOLBAM® in human milk, the effects of CHOLBAM® on the breastfed infant, or the effects of CHOLBAM® on milk production.

There are no animal lactation data and no data from case reports available in the published literature.

Overdosage
In the event of overdose (elevated GGT and ALT), the patient should be monitored and treated symptomatically.

Elevated serum gamma glutamyltransferase (GGT) and serum alanine aminotransferase (ALT) may indicate CHOLBAM® overdose. Continue to monitor laboratory parameters of liver function and consider restarting at a lower dose when the parameters return to baseline.

Please see full prescribing information for CHOLBAM® (cholic acid) 50 mg and 250 mg capsules.

To report SUSPECTED ADVERSE REACTIONS, contact Travere Therapeutics, Inc. at 1-877-659-5518 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.